Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Heghine Khachatryan: What Should We Test From a Hematologic Perspective in Young Cryptogenic Stroke?
Heghine Khachatryan/LinkedIn
Jun 10, 2026, 04:02

Heghine Khachatryan: What Should We Test From a Hematologic Perspective in Young Cryptogenic Stroke?

Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:

“Young Cryptogenic Stroke: What Should We Test from a Hematology Perspective?

The SECRETO study demonstrated that thrombophilia abnormalities are relatively common in young patients with cryptogenic ischemic stroke; however, truly high-risk and persistent abnormalities are uncommon.

These findings support a targeted and clinically driven approach to hematologic evaluation.

Potential hematologic contributors to young cryptogenic stroke include inherited thrombophilia, antiphospholipid syndrome, hyperhomocysteinemia, myeloproliferative neoplasms, paroxysmal nocturnal hemoglobinuria, cancer-associated hypercoagulability, clonal hematopoiesis, elevated factor VIII, hemolysis-associated thrombosis, platelet disorders, and rare fibrinolytic abnormalities.

A reasonable hematologic evaluation in selected patients may include:

  • Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, anti-β2 glycoprotein I antibodies)
  • Inherited thrombophilia testing (Factor V Leiden, Prothrombin G20210A, antithrombin, protein C, protein S)
  • Homocysteine, vitamin B12, and folate
  • Complete blood count, peripheral blood smear, reticulocytes, LDH, bilirubin, and haptoglobin
  • JAK2 V617F, CALR, and MPL mutation analysis when myeloproliferative neoplasms are suspected
  • High-sensitivity flow cytometry for PNH when clinically indicated
  • Age-appropriate evaluation for occult malignancy
  • Selected biomarkers including factor VIII, fibrinogen, D-dimer, lipoprotein(a), and ApoB

Testing is most informative in young patients with recurrent thrombosis, venous thromboembolism, unusual-site thrombosis, pregnancy morbidity, strong family history of thrombosis, unexplained cytopenias, thrombocytosis, erythrocytosis, or laboratory evidence of hemolysis.

The highest diagnostic yield comes not from indiscriminate testing but from a phenotype-driven strategy integrating clinical history, vascular risk factors, and targeted laboratory investigation.”

Heghine Khachatryan: What Should We Test From a Hematologic Perspective in Young Cryptogenic Stroke?

Other posts featuring Heghine Khachatryan on Hemostasis Today.

Antiphospholipid Syndrome cancer-associated hypercoagulability Clonal Hematopoiesis Cryptogenic Stroke elevated factor VIII Health Heghine Khachatryan Hematology hemolysis-associated thrombosis Hemostasis Hemostasis News Hemostasis Today Hyperhomocysteinemia Inherited Thrombophilia Medicine myeloproliferative neoplasms paroxysmal nocturnal hemoglobinuria Platelet disorders SECRETO stroke thrombosis venous thromboembolism
NewsFeed